APA (7th ed.) Citation

V, E., K, H., J, K., S, B., P, K., L, L., . . . HT, S. (2021). Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post-authorization safety cohort study conducted in Europe and in the United States. Pharmacoepidemiology and drug safety, 30(6), 758. https://doi.org/10.1002/pds.5193

Chicago Style (17th ed.) Citation

V, Ehrenstein, et al. "Outcomes in Patients with Lung Cancer Treated with Crizotinib and Erlotinib in Routine Clinical Practice: A Post-authorization Safety Cohort Study Conducted in Europe and in the United States." Pharmacoepidemiology and Drug Safety 30, no. 6 (2021): 758. https://doi.org/10.1002/pds.5193.

MLA (9th ed.) Citation

V, Ehrenstein, et al. "Outcomes in Patients with Lung Cancer Treated with Crizotinib and Erlotinib in Routine Clinical Practice: A Post-authorization Safety Cohort Study Conducted in Europe and in the United States." Pharmacoepidemiology and Drug Safety, vol. 30, no. 6, 2021, p. 758, https://doi.org/10.1002/pds.5193.